F110. SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING

Abstract Background Symptomatic remission (SR) is an important outcome for schizophrenia patients [1]. In pivotal trials, paliperidone 3-monthly formulation (PP3M) demonstrated favorable efficacy and tolerability in schizophrenia, including achievement of SR [2–4]. However, due to the selective nature of randomized clinical trials, populations studied may not be entirely representative of schizophrenia patients in real life. Methods A prospective, single-arm, open-label, 52-week study (REMISSIO) was conducted in a naturalistic setting to assess the impact of conversion from paliperidone palmitate 1-month formulation (PP1M) to PP3M in patients with clinically stable schizophrenia. Patients aged 18–50 years with schizophrenia (DSM-5) were eligible to participate if they had been adequately treated with PP1M for ≥4 months (the last 2 doses of PP1M being the same) and had a baseline Positive and Negative Syndrome Scale (PANSS) total score 6 months v